ABL1 and acute myeloid leukemia: When compared to the 2016 WHO criteria that defined AML as presence of 20% blasts in the bone marrow or peripheral blood in association with any evidence of extramedullary myeloblasts or presence of AML-defining genetic abnormalities irrespective of blast percentage, the updated ICC guideline broadens the genetic abnormalities that define specific AML groups and requires at least 10% blasts in the bone marrow or peripheral blood for defining AML with recurrent genetic abnormalities (with the exception of ≥20% in AML with BCR::ABL1) [18].